Method of enhancing delivery of a therapeutic nucleic acid
View Patent ↗The invention provides methods and compositions for increasing the delivery of nucleic acids into a host by administering a nucleic acid encoding a therapeutic nucleic acid along with an agent that modulates Kupffer cell function in the host.
1. A method for increasing the level of a therapeutic gene product in a subject, the method comprising administering to said subject
(a) a first viral vector comprising a therapeutic nucleic acid encoding said therapeutic gene product, wherein said therapeutic gene product is expressed through operable linkage of said nucleic acid to a promoter, and
(b) an agent that reduces Kupffer cell function, wherein said agent is a second viral vector that does not comprise said therapeutic nucleic acid;
wherein said second viral vector is the same type as said first viral vector;
wherein said agent is administered less than 24 hours prior to or concurrently with administration of said first viral vector;
wherein said first viral vector and said agent are not conjugated;
wherein said agent is administered by a route selected from the group consisting of direct administration to the liver, intravenous administration, or intraperitoneal administration;
wherein said first viral vector and said agent reach the liver following administration; and
wherein levels of said therapeutic gene product are increased in hepatocytes by administration of said agent.
2. The method according to claim 1 , wherein said first and second viral vectors are adenovirus vectors.
3. The method according to claim 1 , wherein said agent is administered less than 24 hours prior to administration of said, first viral vector.
4. The method according to claim 1 , wherein said agent is administered concurrently with administration of said first viral vector.
5. A method for increasing the level of a therapeutic gene product in a subject, the method comprising administering to said subject
(a) a first viral vector comprising a therapeutic nucleic acid encoding said therapeutic gene product, wherein said therapeutic gene product is expressed through operable linkage of said nucleic acid to a promoter, and
(b) an agent that reduces Kupffer cell function, wherein said agent is a second viral vector;
wherein said second viral vector is the same type as said first viral vector;
wherein said agent is administered prior to, but less than 1 hour prior to, administering said first viral vector;
wherein said agent is administered by a route selected from the group consisting of direct administration to the liver, intravenous administration, or intraperitoneal administration;
wherein said first viral vector and said agent reach the liver following administration; and
wherein levels of said therapeutic gene product are increased in hepatocytes by administration of said agent.
6. The method according to claim 5 , wherein said agent is administered less than five minutes prior to administering said first viral vector.
7. The method according to any one of claims 5 - 6 , wherein said first and second viral vectors are adenovirus vectors.
8. The method according to any one of claims 1 or 5 - 6 , wherein said first viral vector is administered by a route selected from the group consisting of oral administration, nasal administration, parenteral administration, transdermal administration, intrabronchial administration, intraperitoneal administration, direct injection into cells, tissue, organ or tumor, intravenous administration, subcutaneous administration, and intramuscular administration.
9. The method according to any one of claims 1 or 5 - 6 , wherein said first and second viral vectors are replication-defective viral vectors.
10. The method according to any one of claims 1 , 5 - 6 , or 2 , wherein said subject is a primate.
11. The method according to claim 10 , wherein said primate is a human.